Textbook of clinical trials: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOEDITSECTION__ | __NOEDITSECTION__ | ||
{{MultiCol}} | |||
'''Ethical Issues''' | '''Ethical Issues''' | ||
Line 38: | Line 38: | ||
[[Phase II clinical trial|Phase 2 trials]] | [[Phase II clinical trial|Phase 2 trials]] | ||
{{ColBreak}} | |||
Advancing from phase 2 to a phase 3 trial | Advancing from phase 2 to a phase 3 trial | ||
Line 68: | Line 69: | ||
Principal investigator role | Principal investigator role | ||
{{ColBreak}} | |||
Executive committee role | Executive committee role | ||
Line 96: | Line 97: | ||
[[Randomization]] | [[Randomization]] | ||
{{ColBreak}} | |||
[[Blinding]] | [[Blinding]] | ||
Line 124: | Line 125: | ||
Study completion and close out | Study completion and close out | ||
{{ColBreak}} | |||
Protocol amendments | Protocol amendments | ||
Line 156: | Line 157: | ||
Net clinical benefit analyses | Net clinical benefit analyses | ||
{{ColBreak}} | |||
Cost effectiveness analyses | Cost effectiveness analyses | ||
Revision as of 13:44, 25 October 2019
Ethical Issues Helsinki agreement Investigational Review Board (IRB) HIPAA reidentification of patients and patient privacy
Regulatory issues and pathways in clinical trials The 1572 form and investigator responsibilities Investigational new drug (IND) application Investigational new drug or device exemption
Designing Clinical Trials Randomized controlled trials versus observational studies Pharmacokinetic (PK) and pharmcodynamic (PD) assessment |
Advancing from phase 2 to a phase 3 trial Parallel versus dose escalation studies Inclusion and exclusion criteria Secondary endpoints and exploratory endpoints Sample size and power calculations Abbreviations used in clinical trials
Operationalizing Clinical Trials Principal investigator role |
Executive committee role Steering committee role Nurse coordinator clinical research associate role Monitor role Sponsor role Randomization service Central laboratory facility EKG core laboratory Angiographic core laboratory MRI core laboratory Genetics core laboratory Biomarker core laboratory Identification of sites |
Recruitment of study participants Schedule of events Concomitant medications Clinical event committee or event adjudication committee Adverse events, serious adverse events and serious unexpected events Data safety monitoring board (DSMB) Study drug discontinuation, withdrawal of consent, incomplete follow up and lost to follow up patients Protocol adherence Storage and handling of investigational product Data management and designing an electronic data capture form Source documents Study completion and close out |
Protocol amendments Publication committee
Statistical Analysis of Clinical Trials Cleaning a dataset Summary statistics Intent to treat versus modified intent to treat versus as treated Student's t tests and analysis of variance Chi square analysis and Fisher's exact test Handling missing data Subgroup and interaction analyses Net clinical benefit analyses |
Cost effectiveness analyses Quality adjusted life year analyses Interim analyses and futility analyses Reporting results and how to write a manuscript Positive publication bias
Study Tools GFR calculationTIMI Risk ScoreGrace Risk Score |